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Abstract  
BACKGROUND: Modern drugs could sometimes be a good solution even to problematic patients. The cutaneous 
and systemic forms of the CD30 positive anaplastic large T-cell lymphoma could often be described as a suitable 
target for therapy with Brentuximab vedotin. 
CASE REPORT: We present the first case of a Bulgarian patient with a histologically confirmed primary 
cutaneous T-cell CD30+/ALK- large anaplastic cell lymphoma-cALCL (therapeutically resistant to therapy with 
Methotrexate, radiation therapy and systemic corticosteroid therapy) who was successfully treated with 
Brentuximab vedotin. In several years, the patient has developed a comparatively fast skin progression as well as 
an initial systemic one which impacts inguinal and mediastinal nodes. After the implementation of 4 therapy cycles 
with Brentuximab vedotin, complete regression of the described by previous hospitalisations lymph nodes as well 
as 80% reduction of the cutaneous and subcutaneous located tumour formations were observed. 
CONCLUSION: The therapy of CD30+/ALK- anaplastic large T-cell lymphoma is a significant challenge for 
oncologists and dermatologists because it requires maximally efficient and minimally traumatic treatment in 
parallel. Therapy with Brentuximab is a new direction which shows extremely good clinical results and can be 
applied to the cutaneous as well as to the systemic form of anaplastic large-cell CD30 positive lymphoma. The 
key element by treatment with Brentuximab is suppression of the CD30- expression which, in turn, could be the 
cause of relapses. On that ground, patients with these lymphomas should be strictly monitored. 
 
 
 
 
 
 
 
 
Introduction 
 
Cutaneous lymphoma treatment is a 
challenge for the clinician and requires an accurate 
assessment of the therapy to achieve optimal 
therapeutic results and a minimum rate of side effects 
[1]. CD-30 and ALK positivity in lymphomas is 
important for the prognosis and choice of treatment 
regimen [1]. 
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Case Report 
 
We at this moment report the case of a 
patient with histologically confirmed primary 
cutaneous T-cell CD30+/ALK- anaplastic large cell 
lymphoma with an available histological verification 
from 2 years ago. From the immunohistochemical 
tests, CD45+, CD3+, CD2+, CD30+, CD20+, EMA+, 
ALK- and Ki67+ reactions were detected. 
Complaints initially began with wide-surface 
erythema in the right lower leg area. Subsequently, 
tumorous papules and a pigmentary solitary tumour 
formation appeared which were treated surgically. 
Concomitant computer tomographic scans did not 
reveal any initial data on the transition to systemic 
lymphoma. Over the last 2 years, 1) 2 corticosteroid 
treatment regimens, 2) 3 radiotherapy courses with a 
total focal dose of 30Gy, and 3) attempted 
Methotrexate 20 mg/week therapy over a total period 
of approximately 2.5 months, were performed, all of 
the currently listed options not leading to any 
symptomatic improvement. Clinical evidence from the 
latest outpatient examination indicated a progression 
of skin symptoms and a slight worsening of the 
general status expressed in subfertility, weakness, 
and severe pain in the muscles and joints. 
The patient was hospitalised for a second 
reevaluation of the diagnosis, ruling out a transition to 
systemic lymphoma, and recommendations for 
introducing a more effective treatment regimen. 
During the clinical examination, multiple, 
partially grouped, as well as single standing nodular 
tumor-like formations with a diameter of between 0.5 
and 3 cm were observed on the skin of the right lower 
leg, which were elastic and dense at palpation, most 
of them with a centrally ulcerated surface, located on 
an erythematous base (Figure 1a). The primary skin 
large anaplastic cell lymphoma (pALCL) diagnosis 
was confirmed again in histologically and 
immunohistochemically. Bone marrow puncture/bone 
marrow flow cytometry analysis showed evidence of 
normocellular and hypercellular bone marrow with no 
immunomorphologic evidence of the involvement of 
the latter from lymphoma. Paraclinical examinations 
showed the following results that made an impression: 
ESR - 22 mm/h; uric acid-plasma - 471.0 μmol/l; 
glycated hemoglobin% - HbA1C - 8.4%; cholesterol-
6.6 mmol/l; LDL - 4.6 mmol/l. 
Computer Tomography scan showed the 
presence of a single 14/11mm paraesophageal lymph 
node, while in the previous scan the latter had a size 
of 18 mm. Additionally, bilaterally enlarged inguinal 
lymph nodes were observed. Primary skin anaplastic 
CD30+ T cell lymphoma was diagnosed with possible 
involvement of the regional lymph nodes. The patient 
received a systemic Brentuximab vedotin therapy, and 
within 3 cycles (each at a 21-day interval), he showed 
a significant improvement of the clinical symptoms 
and involution of the nodular formations in the lower 
limb, as well as normalisation of the lymph node 
dimensions (Figure 1a, 1c). A total of 12 Brentuximab 
cycles were planned. 
 
Figure 1: a) Clinical picture before starting therapy in a patient with 
Methotrexate resistant anaplastic large CD 30 positive ALK-
negative primary cutaneous T cell lymphoma; b) Clinical picture 
after the second Brentuximab infusion; c) Clinical picture after the 3 
Infusion with Brentuximab showing significant clinical improvement 
of the tumourous formations 
 
 
 
Discussion 
 
Anaplastic large cell lymphomas comprise a 
group of CD30-positive non-Hodgkin lymphomas that 
generally are of T-cell origin and share common 
morphologic and phenotypic characteristics [2]. 
The World Health Organization recognises 3 
entities: 1) primary cutaneous ALCL (pcALCL), 2) 
anaplastic lymphoma kinase (ALK)-positive ALCL, 
and, provisionally, 3) ALK-negative ALCL [2]. pcALCL 
presents in the skin and, while it may involve 
locoregional lymph nodes (as in our case suspected), 
rarely disseminates [2]. Outcomes typically are 
excellent [2].  
Anaplastic large‐cell lymphoma (ALCL), 
especially anaplastic lymphoma kinase‐negative 
(ALK
−
) ALCL (as in the case described by us), is a 
rare CD30‐expressing aggressive subtype of 
peripheral T‐cell lymphoma [3]. The CD30 expression 
on the cell surface of ALCL is creating the unique 
possibility for anti-CD30 therapy with Brentuximab (3). 
Brentuximab vedotin (BV; Adcetris
®
 Takeda 
Pharmaceuticals) is a CD30‐directed antibody-drug 
conjugate that received FDA approval in August 2011 
for the treatment of systemic ALCL (sALCL) [3]. 
The advantage of Brentuximab therapy is that 
it is available to patients with both cutaneous and 
systemic form of anaplastic large-cell CD-30 positive 
lymphoma [4] [5]. Both indications (systemic and 
cutaneous) for introducing systemic treatment are of 
significant importance about the clinical management 
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in “problematic patients” [4] [5]. The patient we have 
described did not agree to a biopsy of the 
paraesophageal-localized lymph node and bilaterally 
localised inguinal enlarged lymph nodes.  
During the comparisons of the CT images, it 
was found that the case was most likely related to a 
transition from the cutaneous to the systemic form of 
ALCL. Meanwhile, the two indications for treatment of 
ALCL ensured some freedom of action relating to the 
initiation of innovative Brentuximab therapy, as well as 
optimal clinical outcomes (with complete regression of 
the paraesophageal and bilateral inguinal located 
lymphatic nodes) after 4 cycles with Brentuximab 
vedontin. 
The lack of effectiveness due to the loss of 
CD-30 expression in the course of the targeted 
treatment is a possible reason for relapses in ALCL 
patients, as well as a serious obstacle to continued 
Brentuximab therapy [6].  
Therefore, the progression of the disease 
during the therapy or discontinuation of treatment in 
patients treated with Brentuximab should be 
accompanied by re-testing for CD30 expression in the 
lesional tissue and redefine the therapeutic strategy 
[6]. The patients should be closely monitored. 
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